# Apollomics (APLM) — News

APLM · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/aplm/news

## Recent headlines

- [ApolloMics reports $10M placement transaction](https://www.ainvest.com/news/apollomics-reports-10m-placement-transaction-2608) — AInvest Wire, Aug 11, 2026
- [ApolloMics regains full compliance with Nasdaq listing requirements](https://www.ainvest.com/news/apollomics-regains-full-compliance-nasdaq-listing-requirements-2607) — AInvest Wire, Jul 13, 2026
- [ApolloMics: termination due to Launxp's failure to cure material breach of its obligations under agreement](https://www.ainvest.com/news/apollomics-termination-due-launxp-failure-cure-material-breach-obligations-agreement-2606) — AInvest Wire, Jun 24, 2026
- [ApolloMics Inc: Effective June 11, co formally terminated collaboration & license agreement with Launxp International](https://www.ainvest.com/news/apollomics-effective-june-11-formally-terminated-collaboration-license-agreement-launxp-international-2606-33) — AInvest Wire, Jun 24, 2026
- [Apollomics - regains rights to Vebreltinib (APL-101) in Asia](https://www.ainvest.com/news/apollomics-regains-rights-vebreltinib-apl-101-asia-2606) — AInvest Wire, Jun 24, 2026
  Apollomics Inc. (Nasdaq: APLM) has entered into a licensing agreement with LaunXP Biomedical, granting the latter exclusive rights to develop and commercialize vebreltinib (APL-101) in combination with an EGFR inhibitor in Asia, excluding mainland China, Hong Kong, and Macau. Under the terms of the…

---

Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).